Product Transfer Price. In exchange for the supply of a Product to Codexis pursuant to the EPSA, Codexis shall pay Arch a Product Transfer Price in respect of each Product sold by Codexis to a Codexis Customer equal to
Product Transfer Price. In exchange for the supply of a Product to Codexis India pursuant to the PSA, Codexis India shall pay Arch a Product Transfer Price in respect of each Product sold by Codexis India to a Codexis India Customer equal to:
Product Transfer Price. (a) Transfer Price of CT/GC Outside the United States. During the Term, the transfer price of CT/GC with respect to sales outside the United States shall be [******] of the CT/GC Non-U.S. AUP, subject to [***************************************************].
(b) Transfer Price of CT/GC in the United States. During the Term, the transfer price of CT/GC with respect to sales in the United States shall be [******] of the CT/GC U.S. AUP, subject to [*********** ***************************************].
(c) Transfer Price of HBV. During the Term, the transfer price of HBV shall be [******] of the HBV AUP, subject to [******************** ******************************].
(d) Transfer Price of HPV. During the Term, the transfer price of HPV shall be [******] of the HPV AUP, subject to [******************** ******************************].
Product Transfer Price. The BIOMEDICA price per dose of the Product will be determined by the national competent authority of each country of the Territory in which the Product will be launched. If the price per dose for the Product by the national competent authority is set below ****** then the Parties will renegotiate in good faith the transfer price for Product in that country in the Territory. ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** ****** * Minimum transfer price is set at ****** for the initial five year period ** Governing equation * Confidential Treatment Requested *
Product Transfer Price. The BIOMEDICA price per dose of the Product will be determined by the national competent authority of each country of the Territory in which the Product will be launched. If the price per dose for the Product by the national * Confidential Treatment Requested * competent authority is set below ****** then the Parties will renegotiate in good faith the transfer price for Product in that country in the Territory. * Minimum transfer price is set at ****** for the initial five year period ** Governing equation IS AMENDED AS FOLLOWS:
Product Transfer Price. Cost Schedule for Finished Packaged Goods The transfer price shall be based on the number of patches purchased. Price does not include the API (to be provided by Ferring) nor packaging into Final Commercial Product. [*] o Year one prices to be determined on a blended cost basis across the relevant volume ranges o Subsequent year prices at rate based on total annual purchase during that year. Payment will be on the basis on forecast and any adjustment made within thirty days of year end. o [*] o Minimum purchase of 250,000 patches/year. The above prices are based on the parties' present knowledge regarding the anticipated Product specification and configuration, and current economic conditions. In the event that the anticipated cost to manufacture the Product increases as a result of extraordinary increases in costs of components or materials or changes made to the product specification or configuration such that there is a material change in cost of manufacture, the parties shall, at Vyteris's request, discuss and agree to a fair and equitable upward adjustment to the transfer price schedule set forth in paragraph 1 of this Appendix.
Product Transfer Price. 5.2.1 Aquestive shall Supply quantities of each Unit of the Product to Pharmanovia at each of the initial transfer prices set forth in the Product Schedule (each a “Product Transfer Price”). The Parties agree that upon the earlier of (a) the end of Commercialization Year 3 (as defined in the Product Schedule) and (b) each time an adjustment to the Minimum Volume Commitment, if any, is made pursuant to Section 7.4, the Parties shall discuss and agree upon in good faith a revision to the Product Transfer Price. Thereafter, Aquestive may, after notification to Pharmanovia, increase the Product Transfer Price providing Pharmanovia not less than [****] days written notice of any such proposed increase no more than [****] to the extent necessary to cover actual increases in COGS, as evidenced by relevant supporting documents provided, however, any such price increase shall apply prospectively only and shall not apply to Product subject to binding Purchase Orders. The Parties acknowledge that cost reductions and Product Transfer Price may be possible by improvements in manufacturing processes and increased purchasing resulting from an increase in purchasing volume by Pharmanovia, among other reasons. In the event that Aquestive’s COGS are reduced the Parties shall have a good faith discussion about a proportion reduction in the Product Transfer Price. Thereafter, Aquestive shall, after notification to Pharmanovia, reduce the Product Transfer Price providing Pharmanovia
5.2.2 Notwithstanding the foregoing, if, at any time after the end of the [****] year of this Agreement, Pharmanovia can establish by competent evidence that its Profit/Net Sales in respect of the Product on a [****] month basis has fallen below [****]% for all countries in the Territory, then at Pharmanovia’s request, the Parties agree that for future Purchase Orders: 5.
2.2.1 the Product Transfer Price shall be equal to COGS plus [****]%; and 5.
2.2.2 no further Royalty payments shall be made by Pharmanovia and Pharmanovia shall instead pay to Aquestive a Profit Share as further set out in Section 7.3. 5.3
Product Transfer Price. Aquestive shall Supply quantities of each Unit of the Product to Pharmanovia at the initial Product Transfer Prices below, further to adjustment pursuant to Section 5.2 of the Agreement: Dosage Strength Product Transfer Price Low Dose (5mg, 7.5mg, 10mg) $[****]/per Carton* Medium Dose (12.5mg, 15mg) $[****]/per Carton High Dose (17.5mg, 20mg) $[****]/per Carton
6.1 Milestone Payments Non-refundable payments will be due from Pharmanovia to Aquestive as set forth in the table below: Milestone Milestone Payment (U.S. Dollars) Milestone Payment Due Date 1. Agreement Execution $3,500,000 September 30, 2022 2. Receipt of First Ex-US Marketing Authorization $[****] Within [****] Business Days of receipt of the first Marketing Authorization for the Product within the Territory. 3. Pricing and Reimbursement Milestone $[****] Within [****] Business Days of pricing and reimbursement approval being obtained for the Product from the applicable Regulatory Authority in the first country in the Territory. Pharmanovia shall give Aquestive written notice of the achievement of each milestone event in respect of which a milestone payment is due (with the exception of the first milestone event). Following receipt of such notice, Aquestive shall submit an invoice to Pharmanovia, and Pharmanovia and shall pay the corresponding Milestone Payment no later than five (5) Business Days after receipt of such invoice.
Product Transfer Price. In the event EndoSonics wishes to distribute Product through its direct sales force or through a third party distributor other than JOMED, the parties shall negotiate in good faith a reasonable transfer price to be paid by EndoSonics to JOMED for specified quantities of the Product to be purchased by EndoSonics. Such transfer price shall in no event be less favorable than the price afforded by JOMED to its most favored customer.
Product Transfer Price. Aquestive shall Supply quantities of each Unit of the Product to Haisco at an initial transfer price of [***] per Unit (as same may be adjusted under this Agreement, the “Product Transfer Price”); provided, however, that (i) for orders placed subsequent to an event where a Generic Product is launched in the Field in the Territory by a Third Party, or (ii) orders placed subsequent to an event where the Product is listed in the National Reimbursement List with a price cut required, the Transfer Price shall be reduced by [***] per dose. Aquestive may, after notification to Haisco and good faith discussions with Haisco, increase the Product Transfer Price providing Haisco not less than sixty (60) days written notice of any such proposed increase no more than once annually: (a) by the rate of price increase (if any) indicated by the Producer Price Index applicable to pharmaceutical preparations published by the U.S. Bureau of Labor Statistics, Department of Labor (or any applicable successor index to be agreed to by the Parties in good faith in the event of the discontinuation of same) over the prior twelve (12) month period; and (b) to the extent necessary to cover actual increases in the event that the Unit cost of goods of the Product (determined based on the market price of Aquestive’s Raw Materials) increases by a percentage greater than the change in the Producer Price Index referenced in clause (a) hereof, as evidenced by relevant supporting documents provided, however, any such price increase shall apply prospectively only and shall not apply to Product subject to binding Purchase Orders. Notwithstanding the foregoing, in the event that there will not be reasonable margin for Haisco due to the increase of Product Transfer Price, at the request of Haisco, the Parties shall discuss in good faith adjustment of Product Transfer Price and actions to be taken to control the cost of goods of the Product. Aquestive shall decrease the Product Transfer Price by the rate of price decrease (if any) indicated by the Producer Price Index applicable to pharmaceutical preparations published by the U.S. Bureau of Labor Statistics, Department of Labor (or any applicable successor index to be agreed to by the Parties in writing in good faith in the event of the discontinuation of same) over the prior twelve (12) month period within sixty (60) days after the date that Haisco is eligible for such price decrease; provided, however, any such price decrease shall occur no more...
